Under the agreement, all of Foundation Medicine’s tests, including one for solid tumors and one for hematological malignancies, will be available to veterans. Results from these tests can be used to inform more personalized treatments.
Cindy Perettie, CEO at Foundation Medicine, said in a news release: “Our tests are critical to determining the genomic drivers of cancer and what makes each patient’s disease unique, to enable a personalized treatment approach. It is imperative that every advanced cancer patient has access to this information, and we are privileged to provide our tests to the people who served our country.”
More articles on clinical leadership and infection control:
5 signs of nurse burnout
Patients safer, more satisfied when employees like their hospital, study finds
Viewpoint: Why this nursing ‘rite of passage’ is bullying in disguise
